Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Product revenue	$ 2,366,201	$ 1,852,017
Cost of product sales	928,402	771,005
Gross profit	1,437,799	1,081,012
Operating expenses
Research and development	286,751	504,239
Sales and marketing	511,944	733,913
General and administrative	1,103,143	1,335,292
Total operating expenses	1,901,838	2,573,444
Operating loss	(464,039)	(1,492,432)
Other income (expense), net
Interest Income	48	1,919
Interest Expense, related party	(83,333)	0
Amortization of debt discount	(93,598)	0
Loss from equity-method investment in SAVSU	(229,368)	0
Total other income (expenses), net	(406,251)	1,919
Net loss	(870,290)	(1,490,513)
Net loss attributable to non-controlling interest	0	263,685
Net loss attributable to BioLife Solutions, Inc.	$ (870,290)	$ (1,226,828)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.07)	$ (0.10)
Basic and diluted weighted average common shares used to calculate net loss per common share (in shares)	12,964,639	12,457,858